Table 1.
Baseline characteristics of the study population (N = 140).
Fig 1.
Consort Study Flow Chart.
Fig 2.
Proportion of participants reporting solicited systemic (A) and local (B) adverse events in participants vaccinated with at least one dose of the Ad5-CoV vaccine, after first (left) and second (right) dose.
Table 2.
HIV viral load, CD4 and CD8 cell count measurements at baseline, week 24 and week 52 after the first Ad5-CoV vaccine dose.
Table 3.
S-RBD antibodies at pre-specified time points after vaccination.
Table 4.
SARS-CoV-2 neutralizing antibodies at pre-specified time points after vaccination.